- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07797959
Thread-Embedding Acupuncture as an Adjunct to Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease
28 augustus 2026 bijgewerkt door: Dr Nguyen Ngo Le Minh Anh MD, PhD, University of Science Ho Chi Minh City
Efficacy and Safety of Thread-Embedding Acupuncture as an Adjunct to Proton Pump Inhibitor Therapy in Patients With Gastroesophageal Reflux Disease and Liver-Stomach Stagnation-Heat Syndrome: A Randomized Controlled Trial
This study aims to evaluate the effectiveness of thread-embedding acupuncture combined with omeprazole in patients with gastroesophageal reflux disease (GERD) presenting with the traditional medicine pattern of Liver-Stomach constraint-heat.
Participants will receive either thread-embedding acupuncture combined with omeprazole or the comparator treatment according to the study protocol.
Clinical outcomes will be assessed to determine the effectiveness and safety of the intervention.
Studie Overzicht
Toestand
Werving
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
50
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Minh-Anh Nguyen Ngo Le, MD, PhD
- Telefoonnummer: +84 962 644 648
- E-mail: drminhanh@ump.edu.vn
Studie Locaties
-
-
-
Ho Chi Minh City, Vietnam
- Werving
- Traditional Medicine Hospital of Ho Chi Minh City
-
Contact:
- Hien Thu Thi Le, MD
- Telefoonnummer: +84886725372
- E-mail: mingyingtcm@gmail.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Aged 18 to 60 years.
- Diagnosed with gastroesophageal reflux disease (GERD) with a GerdQ score ≥8 and typical heartburn and/or regurgitation occurring at least 2 days per week, and considered eligible for proton pump inhibitor therapy according to the ACG 2013 guideline.
- Meets the diagnostic criteria for Liver-Stomach Heat Stagnation Syndrome according to the 2017 expert consensus on traditional medicine syndrome differentiation for GERD.
- No previous diagnosis of GERD within the past 8 weeks.
- Voluntarily agrees to participate in the study and provides written informed consent.
Exclusion Criteria:
- Presence of alarm symptoms, including dysphagia, odynophagia, palpable lymph nodes or mass, unintentional weight loss, family history of gastrointestinal malignancy, gastrointestinal bleeding, anemia, or persistent nausea/vomiting.
- Structural gastrointestinal disease confirmed by endoscopy, including esophageal malignancy or other significant organic lesions.
- Current use of medications that may influence GERD assessment or treatment, including glucocorticoids, NSAIDs, bisphosphonates, prostaglandins, oral contraceptives, antifungal agents, or sedative medications.
- Use of proton pump inhibitors, H2-receptor antagonists, or prokinetic agents within the previous 14 days.
- History of hypersensitivity to proton pump inhibitors or absorbable catgut/thread material.
- Skin inflammation, infection, or other dermatologic disease at or around the intended thread-embedding sites.
- Current pregnancy or breastfeeding.
- Currently participating in another interventional clinical study.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Omeprazole
Participants receive omeprazole according to the treatment regimen specified in the study protocol.
|
Participants will receive acupoint catgut embedding in addition to standard treatment with omeprazole.
Acupoint catgut embedding will be performed twice during the 4-week treatment period, at 2-week intervals.
Sterile chromic catgut 3/0 will be embedded at Zhongwan (CV12), Shangwan (CV13), Xiawan (CV10), Zusanli (ST36), Tianshu (ST25), and Taichong (LR3) according to the standardized procedure.
Participants will be monitored for 30 minutes after each procedure for adverse events.
Andere namen:
|
|
Experimenteel: Thread-Embedding Acupuncture Plus Omeprazole
Participants receive thread-embedding acupuncture in combination with omeprazole according to the treatment regimen specified in the study protocol.
|
Participants will receive acupoint catgut embedding in addition to standard treatment with omeprazole.
Acupoint catgut embedding will be performed twice during the 4-week treatment period, at 2-week intervals.
Sterile chromic catgut 3/0 will be embedded at Zhongwan (CV12), Shangwan (CV13), Xiawan (CV10), Zusanli (ST36), Tianshu (ST25), and Taichong (LR3) according to the standardized procedure.
Participants will be monitored for 30 minutes after each procedure for adverse events.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in GERD-Q Score
Tijdsspanne: Baseline and 4 weeks
|
Gastroesophageal reflux disease symptoms will be assessed using the Gastroesophageal Reflux Disease Questionnaire (GerdQ).
The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms.
Change in the total GerdQ score from baseline to 4 weeks will be assessed between the two study groups.
|
Baseline and 4 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Treatment Response Based on GerdQ
Tijdsspanne: Baseline and weekly through 4 weeks
|
Treatment response will be defined as a reduction of at least 2 points in the total Gastroesophageal Reflux Disease Questionnaire (GerdQ) score from baseline.
The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms.
The proportion of participants achieving treatment response will be compared between the two study groups.
|
Baseline and weekly through 4 weeks
|
|
Complete Symptom Resolution Based on GerdQ
Tijdsspanne: 4 weeks
|
Complete resolution of typical gastroesophageal reflux disease (GERD) symptoms will be assessed using the Gastroesophageal Reflux Disease Questionnaire (GerdQ).
The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe GERD symptoms.
Complete symptom resolution will be defined as a score of 0 for both the heartburn and regurgitation items of the GerdQ.
The proportion of participants achieving complete symptom resolution at 4 weeks will be compared between the two study groups.
|
4 weeks
|
|
Change in Traditional Medicine Symptoms of Liver-Stomach Heat Stagnation Syndrome
Tijdsspanne: Baseline and weekly through 4 weeks
|
Traditional medicine symptoms of Liver-Stomach Stagnated Heat syndrome will be assessed using a syndrome symptom score comprising two main symptoms (burning sensation and acid regurgitation) and six secondary symptoms (retrosternal pain, epigastric burning pain, epigastric fullness, belching or food regurgitation, irritability, and rapid hunger).
Each main symptom is rated as absent, mild, moderate, or severe and scored 0, 2, 4, or 6 points, respectively.
Each secondary symptom is rated as absent, mild, moderate, or severe and scored 0, 1, 2, or 3 points, respectively.
The total score ranges from 0 to 30, with higher scores indicating greater syndrome severity.
Change in the total syndrome score from baseline through 4 weeks will be compared between the two study groups.
|
Baseline and weekly through 4 weeks
|
|
Treatment Response Based on Liver-Stomach Stagnated Heat Syndrome Score
Tijdsspanne: Baseline and 4 weeks
|
Treatment response for Liver-Stomach Stagnated Heat syndrome will be assessed using the percentage reduction in the total syndrome score from baseline.
The efficacy index will be calculated as [(baseline score - post-treatment score) / baseline score] × 100.
Clinical cure is defined as an efficacy index of at least 95%, markedly effective as 70% to less than 95%, effective as 30% to less than 70%, and ineffective as less than 30%.
The proportion of participants classified as clinically cured, markedly effective, effective, or ineffective at 4 weeks will be compared between the two study groups.
|
Baseline and 4 weeks
|
|
Adverse Events Associated With Thread-Embedding Acupuncture
Tijdsspanne: Throughout the 4-week treatment period
|
Adverse events associated with thread-embedding acupuncture will be monitored throughout the 4-week treatment period.
Events of interest include local pain, bleeding, bruising, swelling, infection, allergic reactions, and other treatment-related complications.
The number and proportion of participants experiencing at least one adverse event will be recorded and compared between the two study groups.
|
Throughout the 4-week treatment period
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Minh-Anh Nguyen Ngo Le, MD,PhD, University of Medicine and Pharmacy at Ho Chi Minh City
- Hoofdonderzoeker: Minh-Anh Nguyen Ngo Le, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
15 april 2026
Primaire voltooiing (Geschat)
15 september 2026
Studie voltooiing (Geschat)
18 september 2026
Studieregistratiedata
Eerst ingediend
26 augustus 2026
Eerst ingediend dat voldeed aan de QC-criteria
28 augustus 2026
Eerst geplaatst (Werkelijk)
1 september 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
1 september 2026
Laatste update ingediend die voldeed aan QC-criteria
28 augustus 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TEA-GERD-RCT2026
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .